Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression

Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression

Abstract Background Most patients with acute myeloid leukemia (AML) remain uncurable and require novel therapeutic methods. Gain-of-function FMS-like tyrosine kinase 3 (FLT3) mutations are present in 30–40% of AML patients and serve as an attractive therapeutic target. In addition, FLT3 is aberrantl...

Full description

Bibliographic Details
Main Authors: Dengyang Zhang, Yao Guo, Yuming Zhao, Liuting Yu, Zhiguang Chang, Hanzhong Pei, Junbin Huang, Chun Chen, Hongman Xue, Xiaojun Xu, Yihang Pan, Ningning Li, Chengming Zhu, Zhizhuang Joe Zhao, Jian Yu, Yun Chen
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Microbial Cell Factories
Subjects:
FLT3
FL
AML
DM1
Targeted therapy
Online Access:https://doi.org/10.1186/s12934-021-01559-6

Internet

https://doi.org/10.1186/s12934-021-01559-6

Similar Items